Driving subcutaneous self-injection of large volume doses: SCHOTT Pharma
launches large format ready-to-use cartridges for on-body devices

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Market Launch
Driving subcutaneous self-injection of large volume doses: SCHOTT Pharma
launches large format ready-to-use cartridges for on-body devices

16.07.2024 / 10:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Driving subcutaneous self-injection of large volume doses: SCHOTT Pharma
launches large format ready-to-use cartridges for on-body devices

16 July 2024, Germany, Mainz

  * SCHOTT Pharma introduces new 10ml ready-to-use (RTU) cartridges,
    specifically designed to store highly sensitive biologics used to treat
    cancer, metabolic disorders, cardiovascular conditions, genetic
    disorders, and immunological diseases.

  * The proven container compatibility with devices allows patients to
    self-administer drugs in the comfort of their homes for greater patient
    convenience while reducing costs for the healthcare system.

  * Combined with Ypsomed's on-body device YpsoDose, the fully assembled
    system is the first on the market that is prefilled and pre-loaded,
    significantly reducing the handling steps for end-users.

SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery
systems, expands its ready-to-use (RTU) platform with 10ml RTU cartridges.
This large format solution is specifically designed to protect and
administer highly sensitive biologics, which are transforming the treatment
landscape for numerous diseases, including cancer, metabolic disorders,
cardiovascular conditions, genetic disorders, and immunological diseases. By
partnering with device manufacturer Ypsomed, SCHOTT Pharma's new RTU
cartridges are compatible with the on-body device YpsoDose. The fully
assembled device is the first on the market that is prefilled and
pre-loaded, which leads to significantly fewer handling steps for the end
user. "With our large format RTU cartridges, we are actively supporting
pharma companies, who are transitioning the drug administration from
intravenous infusion to subcutaneous injection," says Andreas Reisse, CEO of
SCHOTT Pharma. "We are thereby empowering patients to self-administer also
large volume medications, which is a real game-changer for them. By
facilitating the shift to homecare solutions, we are also helping to reduce
the financial burden on the healthcare system." The RTU cartridges known as
cartriQ® are available for human use (FHU) and are manufactured at the
company's site in St. Gallen, Switzerland.

Currently, there are over 6,200 injectable drugs in the drug development
pipeline, of which roughly 80% are biologics1. These drugs typically feature
a complex molecular structure and must be stored in innovative containers to
ensure drug stability. Moreover, particularly biologics with high viscosity
or those that need to be injected in high volumes require unique solutions
that ensure safe and reliable administration. With the advancements in
biological formulations and delivery devices, a broader range of therapies
can be administered subcutaneously. Thereby enhancing the overall patient
experience and expanding the reach of these innovative treatments.

"Our collaboration with SCHOTT Pharma builds on years of trustful
cooperation. By ensuring proven compatibility of our device with their new
ready-to-use large format cartridges, we're prioritizing patient needs and
enabling the greatest patient convenience," adds Reto Jost, Category Lead
Large Volume Injectors at Ypsomed. At the same time, pharma companies
benefit from a pre-tested and pre-validated solution, which significantly
accelerates the time-to-market of lifesaving drugs.

Expanding high-value solutions portfolio

As part of the SCHOTT iQ® platform, cartriQ® RTU cartridges come in a
standardized nest and tub configuration, ensuring optimal container quality
and enhancing fill-and-finish efficiency for pharma companies. The solution
undergoes stringent in-house steam sterilization to maintain a high level of
sterility. By using steam for the sterilization process, the company is able
to avoid ethylene oxide, which is typically used in the industry, thereby
opting for a more sustainable option. Additionally, cartriQ® is the first
cartridge on the market that features a sterile barrier integrated into the
crimp cap, which eliminates the need for manual swabbing pre-use. This
reduces the handling steps for patients or healthcare professionals, which
saves time and reduces risk for error. The product is part of SCHOTT
Pharma's portfolio of high-value solutions (HVS), which further strengthens
the company's strategic shift towards HVS.

1Source: Globaldata, May 2024

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded
in science to ensure that medications are safe and easy to use for people
around the world. The portfolio comprises drug containment solutions and
delivery systems for injectable drugs ranging from prefillable glass and
polymer syringes to cartridges, vials, and ampoules. Every day, a team of
over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute
to global healthcare. The company is represented in all main pharmaceutical
hubs with 16 manufacturing sites in Europe, North and South America, and
Asia. With over 1,000 patents and technologies developed in-house and a
state-of-the-art R&D center in Switzerland, the company is focused on
developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is
headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange
as part of the SDAX. It is part of SCHOTT AG, which is owned by the Carl
Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to
sustainable development for society and the environment and has the
strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma
has over 1,800 customers including the top 30 leading pharma manufacturers
for injectable drugs and generated revenue of EUR 899 million in the fiscal
year 2023. Further information at www.schott-pharma.com.

Press contact

Joana Kornblum
Media Relations
Tel.: +49 151/29223552
E-Mail: joana.kornblum@schott.com

Jasko Terzic, CFA
Senior Manager Investor Relations
E-Mail: ir.pharma@schott.com


---------------------------------------------------------------------------

16.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        SCHOTT Pharma AG & Co. KGaA
                   Hattenbergstraße 10
                   55122 Mainz
                   Germany
   ISIN:           DE000A3ENQ51
   WKN:            A3ENQ5
   Indices:        SDAX
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Hanover, Munich, Stuttgart, Tradegate
                   Exchange; Vienna Stock Exchange
   EQS News ID:    1946599

End of News EQS News Service
---------------------------------------------------------------------------

1946599 16.07.2024 CET/CEST